| Literature DB >> 23533353 |
Yasunobu Matsuda1, Toshifumi Wakai, Masayuki Kubota, Mami Osawa, Masaaki Takamura, Satoshi Yamagiwa, Yutaka Aoyagi, Ayumi Sanpei, Shun Fujimaki.
Abstract
BACKGROUND: Phosphorylated histone H2AX ( γ -H2AX) is a potential regulator of DNA repair and is a useful tool for detecting DNA damage. To evaluate the clinical usefulness of γ -H2AX in hepatocellular carcinoma (HCC), we measured the level of γ -H2AX in HCC, dysplastic nodule, and nontumorous liver diseases.Entities:
Mesh:
Substances:
Year: 2013 PMID: 23533353 PMCID: PMC3603670 DOI: 10.1155/2013/597095
Source DB: PubMed Journal: ScientificWorldJournal ISSN: 1537-744X
Clinical characteristics of the patient groups of DN and HCC.
| Clinical variables | DN | HCC |
|
|---|---|---|---|
| Mean age (year) | 63 ± 8 | 62 ± 9 | 0.792 |
| Gender | |||
| Male | 13 | 49 | |
| female | 6 | 9 | 0.117 |
| HBs Ag | |||
| + | 2 | 7 | |
| − | 17 | 51 | 0.610 |
| Anti-HCV | |||
| + | 12 | 35 | |
| − | 7 | 23 | 0.525 |
DN: dysplastic nodule; HCC: hepatocellular carcinoma.
*P value of independent Student's t-test for continuous data and Chi2 test for categorical data.
Figure 1γ-H2AX is expressed at different levels in HCC. (a) Immunofluorescence staining shows that phosphorylated histone H2AX (γ-H2AX) is located in the nuclei of HCC cells (green) (original magnification ×100). Case 2: HCC with increased γ-H2AX expression; Case 7: HCC with sparse expression of γ-H2AX. DAPI (blue): nucleus counterstain. (b) Representative data of western blotting for γ-H2AX in liver tissues. H1 and H2: healthy livers; Cases 2 and 7: HCC cases. T: tumor tissues; N: adjacent nontumorous liver tissues. (c) Immunohistochemical staining of γ-H2AX. Cases 1 and 7: HCC cases with negative to low expression of γ-H2AX. Cases 2 and 11: HCCs with high expression of γ-H2AX (original magnification ×40). Arrows indicate positive staining in the nuclei.
Associations of γ-H2AX with clinicopathological features in HCC.
| Clinicopathological variables |
| ||
|---|---|---|---|
| Low | High |
| |
| Age (year) | |||
| <50 | 2 | 4 | |
| ≥50 | 16 | 36 | 0.613 |
| Gender | |||
| male | 15 | 34 | |
| female | 3 | 6 | 0.576 |
| Tumor size (cm) | |||
| <3 | 5 | 11 | |
| ≥3 | 13 | 29 | 0.609 |
| Intrahepatic metastasis | |||
| − | 14 | 30 | |
| + | 4 | 10 | 0.550 |
| Venous invasion | |||
| − | 16 | 37 | |
| + | 2 | 3 | 0.497 |
| Histological grade† | |||
| I/II | 10 | 35 | |
| III/IV | 8 | 5 | 0.011* |
† Histological grade was assessed according to the Edmondson-Steiner grade.
*P value of Chi2 test.
Figure 2γ-H2AX is significantly increased in preneoplastic lesions in the liver. (a) Representative images of immunostaining for γ-H2AX in non-HCC tissues. CH: chronic hepatitis; LC: liver cirrhosis; DN: dysplastic nodule (original magnification ×40). (b) Dot plots showing the γ-H2AX labeling index in normal livers (n = 5), chronic hepatitis (CH; n = 18), liver cirrhosis (LC; n = 22), dysplastic nodule (DN; n = 19), and HCC (n = 58). Horizontal bars depict the mean value, and vertical bars indicate the standard deviation. a**: P value of <0.01 versus normal livers; b**: P value of <0.01 versus dysplastic nodule.
Figure 3γ-H2AX is increased in the adjacent nontumorous liver tissues of HCC patients. (a) Representative data of western blotting for γ-H2AX. L3, 5, and 12: cases with liver cirrhosis without the coexistence of HCC; H3, 5, and 12: adjacent nontumorous liver tissues obtained from HCC patients. (b) Representative images of γ-H2AX immunostaining in liver tissues with and without the coexistence of HCC (original magnification ×40). (c) Dot plots showing the γ-H2AX labeling index. CH: chronic hepatitis without the coexistence of HCC (n = 18) and with HCC (n = 28); LC: liver cirrhosis without HCC (n = 22) and with HCC (n = 30). NS: not significant; **P < 0.01.